Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
Holding GRFS?
Track your performance easily
GRFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.30 - $9.96
Previous CloseN/A
Volume119.87K
Average Volume (3M)791.93K
Market Cap
$5.73B
Enterprise ValueN/A
Total Cash (Recent Filing)$895.01M
Total Debt (Recent Filing)$4.68B
Price to Earnings (P/E)29.0
Beta1.34
Next Earnings
Feb 27, 2025EPS Estimate
0.23Last Dividend Ex-Date
Jun 03, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding261,425,100
10 Day Avg. Volume665,832
30 Day Avg. Volume791,935
Standard Deviation0.12
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.74
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Grifols SA News
Ownership Overview
―
Insiders
8.57% Mutual Funds
35.41% Other Institutional Investors
55.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $5.30 and its highest was $9.96 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $5.73B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is Feb 27, 2025 which is in 39 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on Nov 07, 2024. The company reported $0.173 earnings per share for the quarter, missing the consensus estimate of $0.216 by -$0.043.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.345 which represents an annual dividend yield of N/A. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.23.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.173 in its last earnings report, missing expectations of $0.216. Following the earnings report the stock price went up 4.972%.
Which hedge fund is a major shareholder of Grifols SA?
Among the largest hedge funds holding Grifols SA’s share is Brandes Investment Partners LP. It holds Grifols SA’s shares valued at 177M.
---
Grifols SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
GRFS Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 931.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.10%
Trailing 12-Months
Company Description
Grifols SA
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
---
GRFS Company Deck
---
GRFS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong performance in revenue growth and EBITDA improvement, with strategic achievements in innovation and deleveraging. However, significant financial expenses and ongoing challenges in free cash flow generation present concerns. The situation in China also requires careful monitoring.Read More>---
GRFS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Baxter International
―
Novartis
―
Johnson & Johnson
―
Pfizer
―
Merck & Company
―
Illumina
―
Best Analysts Covering GRFS
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-13.58%
reiterated a buy rating 6 months ago
Copying Tom Jones's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -13.58% per trade.
---